Director & 10% Owner Boosts AKTS Stake by Over $125M, Signaling Strong Confidence
AKTS is trading near its 52-week low of $19.333 (14% above the low).
Summary
Director and 10% owner Kim Helen Susan significantly increased her stake in Aktis Oncology, Inc. through a combination of open market purchases and preferred stock conversions, totaling over $125 million in common stock.
Key Events · Ownership and Investor Activity · AKTS
-
Significant Insider Investment
Director and 10% owner Kim Helen Susan acquired common stock totaling $125,252,259.
-
Open Market Purchase
The acquisition included an open market purchase of 835,000 shares at $18.00 per share, valued at $15,030,000.
-
Preferred Stock Conversion
Preferred stock was converted into 4,994,212 shares of common stock, further increasing common equity holdings.
-
Substantial Stake Increase
The total acquisition represents 10.964% of the company's market capitalization, indicating strong insider confidence.
Analysis · AKTS · Life Sciences
Director and 10% owner Kim Helen Susan has made a highly significant investment in Aktis Oncology, Inc., acquiring common stock valued at over $125 million. This substantial increase in holdings, representing nearly 11% of the company's market capitalization, signals strong conviction in the company's future prospects. The acquisition includes both direct open market purchases and the conversion of preferred stock into common shares, demonstrating a deep commitment from a key insider. Investors should view this as a strong vote of confidence, particularly given the magnitude of the capital deployed.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTS was trading at $22.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.33 to $29.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.